This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
The Zacks Analyst Blog Highlights ADMA, FirstCash, Stride, Life Time Group and National Fuel Gas
by Zacks Equity Research
ADMA, FirstCash, Stride, Life Time Group and National Fuel Gas are included in this Analyst Blog.
Sage Therapeutics' Q1 Earnings Miss Mark, Revenue Rise Y/Y
by Zacks Equity Research
SAGE's earnings and revenues miss estimates in the first quarter of 2025. The company focuses on the commercialization of its depression drug Zurzuvae.
Repligen's Q1 Earnings Beat Estimates, Revenues Surge Y/Y
by Zacks Equity Research
RGEN reports better-than-expected first-quarter results. The company increases its total revenue (on a reported basis) guidance for 2025.
These 5 Buy-Ranked Mid-Cap Stocks Are Flying High Year to Date
by Nalak Das
Five mid-cap high-flying stocks to buy are: ADMA, FCFS, LRN, LTH, NFG.
Adma Biologics (ADMA) Stock Slides as Market Rises: Facts to Know Before You Trade
by Zacks Equity Research
Adma Biologics (ADMA) closed the most recent trading day at $24.11, moving -1.63% from the previous trading session.
GILD Down on Q1 Earnings and Sales Miss, Oncology Sales Decline
by Zacks Equity Research
Gilead Sciences' Q1 earnings and sales miss estimates on lower oncology drug sales. The stock is trading down.
BMY Beats on Q1 Earnings and Sales, Raises 2025 Outlook
by Zacks Equity Research
BMY beats on both earnings and sales in the first quarter of 2025. The company raises its guidance for the full year.
Adma Biologics (ADMA) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Adma Biologics (ADMA) closed at $21.73, marking a +1.57% move from the previous day.
Adma Biologics (ADMA) Beats Stock Market Upswing: What Investors Need to Know
by Zacks Equity Research
Adma Biologics (ADMA) concluded the recent trading session at $21.31, signifying a +0.38% move from its prior day's close.
GSK's Pentavalent Meningococcal Jab Recommended for Use by ACIP
by Zacks Equity Research
The U.S. CDC's Advisory Committee recommends the use of GSK's pentavalent Penmenvy vaccine as part of the adolescent meningococcal vaccination schedule.
MURA Soars as it Explores Strategic Options Post Cancer Study Failures
by Zacks Equity Research
Mural Oncology stock skyrockets after it begins exploring strategic alternatives to maximize shareholder value after the failure of two cancer studies for nemvaleukin alfa.
Adma Biologics (ADMA) Is Considered a Good Investment by Brokers: Is That True?
by Zacks Equity Research
The average brokerage recommendation (ABR) for Adma Biologics (ADMA) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
DTIL Gets FDA's Fast Track Tag for Hepatitis B Gene Therapy, Stock Up
by Zacks Equity Research
Precision BioSciences stock soars 24% as the FDA grants the Fast Track designation to its PBGENE-HBV gene therapy for potentially curing chronic hepatitis B.
VERV Stock Soars on Superior Efficacy in Phase I Cholesterol Study
by Zacks Equity Research
Verve Therapeutics stock rises on demonstrating superior LDL-C lowering ability in a phase Ib study of VERVE-102 in patients with HeFH and/or CAD.
Fate Therapeutics' Lupus Candidate FT819 Gets FDA RMAT Tag
by Zacks Equity Research
The FDA bestows a Regenerative Medicine Advanced Therapy tag on FATE's pipeline candidate, FT819, for treating moderate-to-severe systemic lupus erythematosus.
Are Medical Stocks Lagging ADMA Biologics (ADMA) This Year?
by Zacks Equity Research
Here is how Adma Biologics (ADMA) and Agilon Health (AGL) have performed compared to their sector so far this year.
Adma Biologics (ADMA) Just Overtook the 20-Day Moving Average
by Zacks Equity Research
When a stock breaks out above the 20-day simple moving average, good things could be on the horizon. How should investors react?
Ironwood Shares Tank on Regulatory Update for Apraglutide
by Zacks Equity Research
Per the latest discussion with the FDA, a confirmatory phase III study is required to seek approval for IRWD's apraglutide in short bowel syndrome with intestinal failure.
Adma Biologics (ADMA) Moves 7.8% Higher: Will This Strength Last?
by Zacks Equity Research
Adma Biologics (ADMA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Adma Biologics (ADMA) is on the Move, Here's Why the Trend Could be Sustainable
by Zacks Equity Research
If you are looking for stocks that are well positioned to maintain their recent uptrend, Adma Biologics (ADMA) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Roche Gets Nod for Expanded Use of Columvi in Lymphoma in Europe
by Zacks Equity Research
The European Commission approves RHHBY's Columvi combo to treat adult patients with diffuse large B-cell lymphoma after initial therapy.
NVS Plans to Invest $23B in US Manufacturing Sites Amid Tariff Threat
by Zacks Equity Research
Novartis plans to expand its current manufacturing, research and technology presence in the United States following Trump's announcement of tariffs on pharmaceutical imports.
KROS Initiates Exploring Strategic Alternatives, Stock Gains 18.5%
by Zacks Equity Research
The stock rallies 18.5% after Keros initiates a strategic review process exploring alternatives, including a potential sale of the business.
Arcturus Gets FDA's Fast Track Tag for Influenza Vaccine Candidate
by Zacks Equity Research
The FDA bestows a Fast Track designation to ARCT's sa-mRNA vaccine candidate, ARCT-2304, for active immunization to prevent pandemic influenza A virus H5N1.
PHIO Stock Soars as Safety Panel Clears Skin Cancer Drug for Next Dose
by Zacks Equity Research
Phio Pharmaceuticals stock rallies as safety committee gives green light to advance skin cancer candidate to next dose concentration in phase I study.